SP01-20: A Latest Patent-Based Snapshot of Research and Development of Chimeric Antigen Receptor (CAR)-T cell Therapy
University of Macau Macao
Chimeric antigen receptor T cell immunotherapy revolutionized cancer therapy.The technological bottlenecks of treating solid tumors and alleviating side effects raise the question of whether CAR-T moves down to a flat stage.The study focuses on highlighting the trends of R&D on CAR-T immunotherapy.
All patents were sampled from Derwent Innovation following PRISMA criteria since 2010 and further analyzed, using descriptive statistics, citation network, and collaboration network. Research results are reported in accordance with Reporting Items for Patents Landscapes (RIPL) statement.
Totally, 8511 patent files were retrieved in this analysis. CAR-T patents showed a remarkable rapid growth in the past decade. This research listed top inventors, assignees, and clusters of CAR-T patents, in which University of Pennsylvania and Novartis act as the most notable collaborative players. This kind of academia-industry partnership has been the most dominant collaborative pattern, accounting for 46.32% of all collaborations in 2018. As more and more important role of non-commercial players in CAR-T, the cooperation relevant to non-commercial institutions has reached 85.79% in total in 2018. From the spatial angle, the United States hold the most patents either by assignees or by priority regions, linked to other countries most widely, covered all relevant targets, and conveyed the majority of top inventors and assignees. It is worth noting that China surpassed United States in 2018 by receiving 455 patent applications worldwide. From the technological angle, CD19 is the most frequently involved target, while patents with the most citations from 2016 to 2018 show that improving cell performance and industrial preparation have become new research hotspots.
CAR-T immunotherapy is a field of cancer treatment with great potential, and the number of patent applications is growing explosively.With a rapid development in the past decade, CAR-T immunotherapy has become a hot area where commercial corporates compete fiercely and university-industry collaborates intensively. An open innovation model highlighting academia-industry partnership has been well established in CAR-T area. The United States is in the leading position and holds the most patents, is linked to other countries most widely, covered all relevant targets, and had the majority of top inventors and assignees. China is attracting increasing numbers of patent applications and in 2018 overtook the United States by this metric for the first time, though no therapy has been launched so far. CD19 is the most frequent target, while exploring multiple targets, improving cell performance and industrial preparation have become new research hotspots.